Hope E Burks, Margarite D Matossian, Lyndsay Vanhoy Rhodes, Theresa Phamduy, Steven Elliott, Aaron Buechlein, Douglas B Rusch, David F B Miller, Kenneth P Nephew, Douglas Chrisey, Bridgette M Collins-Burow, Matthew E Burow
PURPOSE: The transcription factors ZEB1 and ZEB2 mediate epithelial-to-mesenchymal transition (EMT) and metastatic progression in numerous malignancies including breast cancer. ZEB1 and ZEB2 drive EMT through transcriptional repression of cell-cell junction proteins and members of the tumor suppressive miR200 family. However, in estrogen receptor positive (ER +) breast cancer, the role of ZEB2 as an independent driver of metastasis has not been fully investigated. METHODS: In the current study, we induced exogenous expression of ZEB2 in ER + MCF-7 and ZR-75-1 breast cancer cell lines and examined EMT gene expression and metastasis using dose-response qRT-PCR, transwell migration assays, proliferation assays with immunofluorescence of Ki-67 staining...
July 6, 2021: Breast Cancer Research and Treatment